Espen A. Haavardsholm

Professor |
Center manager REMEDY https://orcid.org/0000-0002-1427-4745

See Google Scholar profile

See publications in PubMed

Education

Doctor at the University of Oslo (professional study in medicine)
Doctoral degree at the Department of Clinical Medicine, University of Oslo

Position

Head of Centre, Research Center for Treatment in Rheumatology and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital
Head of department for research and innovation, Clinic for rheumatology, outpatient clinic and research, Diakonhjemmet hospital
Professor II, Department of Clinical Medicine, University of Oslo

Field of interest

Rheumatology
Musculoskeletal diseases
Osteoarthritis
Randomized clinical trials
Register studies
Image diagnostics
Translational research

Other

President, Scandinavian Society of Rheumatology
Chairman, Stiftelsen Scandinavian Rheumatology Association
Board member, Norwegian Rheumatology Association

Email

This email address is protected from programs that collect email addresses. You need JavaScript enabled to view it.

Telephone

+47 99798329

visiting address

Diakonhjemmet hospital
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo

Postal address

Diakohjemmet hospital
PO Box 23 Vinderen
0319 Oslo

Projects

WP1 - Optimized medical interventions

ARCTIC FORWARD

10-year follow-up of patients with rheumatoid arthritis who received structured treatment-to-target therapy in the early disease phase.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercise ullamco laboris nisi ut aliquip ex ea commodo consequat.

WP1 - Optimized medical interventions

ARCTIC REWIND

10-year follow-up of patients with rheumatoid arthritis who received structured treatment-to-target therapy in the early disease phase.

WP2 - PPhenotyping for personalized medicine

BIKE

Biopsies of synovitis in the knee joint from patients with RA and OA

WP1 - Optimized medical interventions

MERINO

Methotrexate in the treatment of erosive hand osteoarthritis

WP1 - Optimized medical interventions

MethMax

Maximization of treatment effect

WP1 - Optimized medical interventions

MinJIA

Strategies for personalized treatment of juvenile idiopathic arthritis (JIA)

WP1 - Optimized medical interventions

NOR-CACTUS

Comparison of treatment strategies in carpal tunnel syndrome

WP6 - Dechiphering long-term outcomes

NOR-DMARD

The Norwegian register for antirheumatic drugs

WP2 - PPhenotyping for personalized medicine

NOR DRUM

The Norwegian study for therapeutic drug monitoring

WP5 - Innovative approaches to remote care

NOR Flare

Distance follow-up of patients with rheumatoid arthritis

WP6 - Dechiphering long-term outcomes

NOR Gout

Gout in Norway

WP1 - Optimized medical interventions

NOR Sprint

Follow-up of newly diagnosed patients with psoriatic arthritis with and without imaging

WP2 - PPhenotyping for personalized medicine

Nor-vaC

Immunological response to COVID-19 vaccine in patients on immunosuppressive treatment

WP1 - Optimized medical interventions

NORTH STAR

The Nordic study of strategy tests and registries for rheumatic diseases

WP1 - Optimized medical interventions

PICASSO

Treatment of painful inflammatory carpometacarpal-1 osteoarthritis with intra-articular steroids, saline or occupational therapy

WP1 - Optimized medical interventions

RA DRUM

Therapeutic drug monitoring in patients with rheumatoid arthritis (RA-DRUM)

WP5 - Innovative approaches to remote care

ReMonit

remote monitoring of patients with spondyloarthritis

WP2 - PPhenotyping for personalized medicine

RIMRA

Rheumatic immune-related side effects in patients treated with immunotherapy

WP1 - Optimized medical interventions

SQUEEZE

Maximizing the effect of prescription drugs in rheumatoid arthritis

WP2 - PPhenotyping for personalized medicine

START

Stratification of acute inflammatory arthritis

Publications

Publications taken from the National Science Archive (NVA):

Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomized controlled, non-inferiority trial

2024

Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyzes of the randomised, controlled NOR-DRUM trials

2024

Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study

2024

Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to flares in disease activity

2024

Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study

2024

Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study

2024

Glossary of national professional guidelines from the Norwegian Directorate of Health

2024

Presentation of the first international research network to foster high-quality clinical trials testing non-pharmacological interventions (TRACTION network)

2024

Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomized controlled trial

2024

Agreement between patient-reported flares and clinically significant flare status in patients with rheumatoid arthritis in sustained remission: data from the ARCTIC REWIND trials

2024

T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study

2024

Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes - results from the NOR-Gout study

2024

Circulating Baseline CXCR3 ⁺ Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis

2024

Circulating Adipokines and Response to Treatment in Patients With Early Rheumatoid Arthritis

2024

Therapeutic serum level for adalimumab in rheumatoid arthritis: exploratory analyzes of data from a randomized phase III trial

2024

Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial

2023

Follow-Up of Patients With Axial Spondyloarthritis in Specialist Health Care With Remote Monitoring and Self-Monitoring Compared With Regular Face-to-Face Follow-Up Visits (the ReMonit Study): Protocol for a Randomized, Controlled Open-Label Noninferiority Trial

2023

Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study

2023

Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases

2023

Course and predictors of work productivity in gout - results from the NOR-Gout longitudinal 2-year treat-to-target study

2023

Effect of tapered versus stable treatment with tumor necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial

2023

Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010–2019)

2023

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomized controlled NORD-STAR trial

2023

Calprotectin, a sensitive marker of inflammation, is robustly assessed in plasma from patients with early or established rheumatoid arthritis by use of different laboratory methods

2023

Beliefs about medicines in gout patients: results from the NOR-Gout 2-year study

2023

Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis and Excellent Disease Control

2023

HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases

2023

Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study

2022

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

2022

All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study

2022

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

2022

Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study

2022

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

2022

The MCP2 and the wrist plus two extensor compartments are the most affected and responsive joints/tendons out of the US7 score in patients with rheumatoid arthritis-an observational study

2022

Risk factors for anti-drug antibody formation to infliximab: Secondary analyzes of a randomized controlled trial

2022

Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy

2022

Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomized controlled trial

2022

Using observational study data as an external control group for a clinical trial: an empirical comparison of methods to account for longitudinal missing data

2022

Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study

2022

Impact of delayed type hypersensitivity arthritis on development of heart failure by aortic constriction in mice

2022

Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents

2022

One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study

2022

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study

2022

Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010–2019 – a country with a national tender system for prescription of costly drugs

2022

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

2021

Two-year reduction of dual-energy CT urate deposits during a treat-to-target strategy in gout in the NOR-Gout longitudinal study.

2021

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

2021

Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis

2021

Incidence, sociodemographic factors and treatment penetration of rheumatoid arthritis and psoriatic arthritis in Norway.

2021

Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.

2021

Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment

2021

12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: Achievements of the urate target levels and predictors of obtaining this target

2021

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients with Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial

2021

MicroRNA Expression Differences in Blood-Derived CD19+ B Cells of Methotrexate Treated Rheumatoid Arthritis Patients

2021

Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy

2021

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

2021

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (The NOR-DRUM study)

2020

Active conventional treatment and three different biological treatments in early rheumatoid arthritis: Phase IV investigator initiated, randomised, observer blinded clinical trial

2020

Conventional versus ultrasound treat to target: No difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis

2020

Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study

2020

The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial

2020

Efficacy and safety of CT-P13 in inflammatory bowel disease after switching from originator infliximab: Exploratory analyzes from the NOR-SWITCH main and extension trials

2020

Achievement of Remission in Two Early Rheumatoid Arthritis Cohorts Implementing Different Treat-to-Target Strategies

2020

Rheumatoid Arthritis Patients, Both Newly Diagnosed and Methotrexate Treated, Show More DNA Methylation Differences in CD4+ Memory Than in CD4+ Naïve T Cells

2020

Trends in All-Cause and Cardiovascular Mortality in Patients With Incident Rheumatoid Arthritis: A 20-year Follow-Up Matched Case-Cohort Study

2019

Validity and responsiveness of combined inflammation and combined joint damage scores based on the OMERACT rheumatoid arthritis MRI scoring system (RAMRIS)

2019

Peptidylarginine deiminase 4 (PAD4) activity in early rheumatoid arthritis

2019

Subclinical treatment targets in rheumatology: Lessons from randomized clinical trials in rheumatoid arthritis

2019

Assessing synovitis in the hands in patients with rheumatoid arthritis by ultrasound: an agreement study exploring the most inflammatory active side from two Norwegian trials

2019

Swollen, but not tender joints, are independently associated with ultrasound synovitis: Results from a longitudinal observational study of patients with established rheumatoid arthritis

2019

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial

2019

Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial

2018

Comparative analyzes of responsiveness between the Rheumatoid Arthritis Impact of Disease score, other patient-reported outcomes and disease activity measures: secondary analyzes from the ARCTICstudy

2018

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study

2018

Confiance des rhumatologues quant au passage a un biosimilaire

2018

Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol

2018

The impact of ultrasound on the use and efficacy of intraarticular glucocorticoid injections in early rheumatoid arthritis: Secondary analyzes from a randomized trial examining the benefit of ultrasound in a clinical tight control regimen

2018

The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy

2018

Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: Associations to future good radiographic and physical outcomes

2018

Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: Study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study

2017

The OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging (MRI) Scoring System: Updated Recommendations by the OMERACT MRI in Arthritis Working Group

2017

Development and Validation of the OMERACT Rheumatoid Arthritis Magnetic Resonance Tenosynovitis Scoring System in a Multireader Exercise

2017

Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis

2017

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

2017

Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria

2017

Educational needs and preferences of young European clinicians and physician researchers working in the field of rheumatology

2016

Ultrasound in the management of rheumatoid arthritis: ARCTIC randomized controlled strategy trial

2016

Development of a feasible and responsive ultrasound inflammation score for rheumatoid arthritis through a data-driven approach

2016

Diagnosis and management of rheumatoid arthritis; What is the current role of established and new imaging techniques in clinical practice?

2016

Espen A. Haavardsholm

Education

Position

Field of interest

Other

Email

Telephone

visiting address

Postal address

Projects

Publications

Publications taken from the National Science Archive (NVA):

Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomized controlled, non-inferiority trial

Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyzes of the randomised, controlled NOR-DRUM trials

Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study

Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to flares in disease activity

Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study

Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study

Glossary of national professional guidelines from the Norwegian Directorate of Health

Presentation of the first international research network to foster high-quality clinical trials testing non-pharmacological interventions (TRACTION network)

Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomized controlled trial

Agreement between patient-reported flares and clinically significant flare status in patients with rheumatoid arthritis in sustained remission: data from the ARCTIC REWIND trials

T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study

Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes - results from the NOR-Gout study

Circulating Baseline CXCR3 + Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis

Circulating Adipokines and Response to Treatment in Patients With Early Rheumatoid Arthritis

Therapeutic serum level for adalimumab in rheumatoid arthritis: exploratory analyzes of data from a randomized phase III trial

Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial

Follow-Up of Patients With Axial Spondyloarthritis in Specialist Health Care With Remote Monitoring and Self-Monitoring Compared With Regular Face-to-Face Follow-Up Visits (the ReMonit Study): Protocol for a Randomized, Controlled Open-Label Noninferiority Trial

Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study

Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases

Course and predictors of work productivity in gout - results from the NOR-Gout longitudinal 2-year treat-to-target study

Effect of tapered versus stable treatment with tumor necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial

Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010–2019)

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomized controlled NORD-STAR trial

Calprotectin, a sensitive marker of inflammation, is robustly assessed in plasma from patients with early or established rheumatoid arthritis by use of different laboratory methods

Beliefs about medicines in gout patients: results from the NOR-Gout 2-year study

Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis and Excellent Disease Control

HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases

Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

The MCP2 and the wrist plus two extensor compartments are the most affected and responsive joints/tendons out of the US7 score in patients with rheumatoid arthritis-an observational study

Risk factors for anti-drug antibody formation to infliximab: Secondary analyzes of a randomized controlled trial

Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy

Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomized controlled trial

Using observational study data as an external control group for a clinical trial: an empirical comparison of methods to account for longitudinal missing data

Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study

Impact of delayed type hypersensitivity arthritis on development of heart failure by aortic constriction in mice

Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents

One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study

Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010–2019 – a country with a national tender system for prescription of costly drugs

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

Two-year reduction of dual-energy CT urate deposits during a treat-to-target strategy in gout in the NOR-Gout longitudinal study.

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis

Incidence, sociodemographic factors and treatment penetration of rheumatoid arthritis and psoriatic arthritis in Norway.

Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.

Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment

12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: Achievements of the urate target levels and predictors of obtaining this target

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients with Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial

MicroRNA Expression Differences in Blood-Derived CD19+ B Cells of Methotrexate Treated Rheumatoid Arthritis Patients

Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (The NOR-DRUM study)

Active conventional treatment and three different biological treatments in early rheumatoid arthritis: Phase IV investigator initiated, randomised, observer blinded clinical trial

Conventional versus ultrasound treat to target: No difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis

Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study

The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial

Efficacy and safety of CT-P13 in inflammatory bowel disease after switching from originator infliximab: Exploratory analyzes from the NOR-SWITCH main and extension trials

Achievement of Remission in Two Early Rheumatoid Arthritis Cohorts Implementing Different Treat-to-Target Strategies

Rheumatoid Arthritis Patients, Both Newly Diagnosed and Methotrexate Treated, Show More DNA Methylation Differences in CD4+ Memory Than in CD4+ Naïve T Cells

Trends in All-Cause and Cardiovascular Mortality in Patients With Incident Rheumatoid Arthritis: A 20-year Follow-Up Matched Case-Cohort Study

Validity and responsiveness of combined inflammation and combined joint damage scores based on the OMERACT rheumatoid arthritis MRI scoring system (RAMRIS)

Peptidylarginine deiminase 4 (PAD4) activity in early rheumatoid arthritis

Subclinical treatment targets in rheumatology: Lessons from randomized clinical trials in rheumatoid arthritis

Circulating Baseline CXCR3 ⁺ Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis